B.A., 1972, University of Kansas, Chemistry
Ph.D., 1977, University of Kansas, Experimental Pathology
Postdoctoral Fellow, 1977-1980, University of Californai San Francisco
Our laboratory has used the power of mass spectrometry (MS) coupled to liquid or gas chromatography to measure amounts of drugs, drug metabolites and other xenobiotics in biological samples. We often use this technology to provide analytical services to other investigators, either commercially or collaboratively. When funding for research is obtained, we have used MS techniques to study in vitro drug metabolism. This includes use of animal models, human liver microsomes, cDNA-expressed drug metabolizing enzymes and human clinical studies. We have examined the role of cytochrome P450s (CYP) 2D1 in rat metabolism of amphetamine, the involvement of different in CYPs in the metabolism of l-acetylmethadol (LAAM) and methadone, and the involvement of both CYPs and glucuronosyltransferases (UGT) in the metabolism of buprenorphine. Currently we are studying in vitro inhibition of the metabolism of oxycodone, methadone and buprenorphine.
Chang, Y. and Moody, D.E. Glucuronidation of buprenorphine and norbuprenorphine by human liver microsomes and UGT supersomes. Drug Metab. Lett. 3: 101-107, 2009.
Moody, D.E., Chang, Y., Huang, W. and McCance-Katz, E.F. The in vivo response of novel buprenorphine metabolites, M1 and M3, to antiretroviral inducers and inhibitors of buprenorphine metabolism. Bas. Clin. Pharmacol. Toxicol. 105: 211-215, 2009.
Chang, Y., Moody, D.E. and McCance-Katz, E.F. Novel metabolites of buprenorphine detected in human liver microsomes and human urine. Drug Metab. Dispos.34: 440-448, 2006.
Huang, W., Moody, D.E. and McCance-Katz, E.F. The in vivo glucuronidation of buprenorphine and norbuprenorphine determined by liquid chromatography-electrospray ionisation-tandem mass spectrometry. Ther. Drug Monit.28: 245-251, 2006.
Chang, Y. and Moody, D.E. Effect of benzodiazepines on the metabolism of buprenorphine in human liver microsomes. Eur. J. Clin. Pharmacol.60: 875-881, 2005.
Moody, D.E., Walsh, S.L., Rollins, D.E., Neff, J.A. and Huang, W. Ketoconazole, a cytochrome P450 3A4 inhibitor, markedly increases concentrations of l-acetyl-α-methadol (LAAM) in opioid-naïve individuals. Clin. Pharmacol. Ther.76: 154-166, 2004.
Neff, J.A. and Moody, D.E. Differential N-demethylation of l-α-acetylmethadol (LAAM) and norLAAM by cytochrome P450s 2B6, 2C18 and 3A4. Biochem. Biophys. Res. Commun. 284: 751-756, 2001.
Law, M.Y.L., Slawson, M.H. and Moody, D.E. The selective involvement of the cytochrome P450 2D subfamily in the in vivo 4-hydroxylation of amphetamine in the rat. Drug Metab. Dispos. 28: 348-353, 2000.
Moody, D.E., Alburges, M.E., Parker, R.J., Collins, J.M. and Strong, J.M. The involvement of cytochrome P450 3A4 in the N-demethylation of l-α-acetylmethadol (LAAM), norLAAM and methadone. Drug Metab. Dispos. 25: 1347-1353, 1997.
Moody, D.E., Fang, W.B., Lin, S.N., Weyant, D.M., Strom, S.C. and Omiecinski, C.EJ. The effect of rifampin and nelfinavir on the metabolism of methadone and buprenorphine in primary cultures of human hepatocytes. Drug Metab. Dispos. 37: 2323-2329, 2009.
Chang, Y., Fang, W.B., Lin, S.N. and Moody, D.E. Stereo-selective metabolism of methadone by human liver microsomes and cDNA-expressed cytochrome P450s: A reconciliation. Bas. Clin. Pharmacol. Toxicol. 108: 55-62, 2011.